Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
206 hedge funds and large institutions have $3.36B invested in Amicus Therapeutics in 2019 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 93 increasing their positions, 37 reducing their positions, and 36 closing their positions.
151% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 37
14% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 36
12% more call options, than puts
Call options by funds: $12.8M | Put options by funds: $11.5M
0% more funds holding
Funds holding: 205 → 206 (+1)
1% less capital invested
Capital invested by funds: $3.41B → $3.36B (-$50.8M)
6.06% less ownership
Funds ownership: 112.02% → 105.96% (-6.1%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$40.7M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$40.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$38.4M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$37.5M |
| 5 |
Morgan Stanley
New York
|
+$32.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$104M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$39.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$20.8M |
| 4 |
Millennium Management
New York
|
-$15.7M |
| 5 |
Jennison Associates
New York
|
-$9.66M |
FOLD Hedge Fund Activity: Q2 2019 in Review
206 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2019, worth a combined $3.36B — down 1.5% from $3.41B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new FOLD positions and 36 closed out — a net gain of 5 holders — while 93 added to existing stakes and 37 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $40.7M. The largest seller was Fidelity Investments, cutting an estimated $104M.
- 206 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2019, up from 205 in Q1 2019.
- Funds reported $3.36B of Amicus Therapeutics stock for Q2 2019, down 1.5% quarter-over-quarter.
- 41 funds opened new Amicus Therapeutics positions in Q2 2019 and 36 closed out, a net change of +5 holders.
- The largest Amicus Therapeutics buyer in Q2 2019 was Deutsche Bank, an estimated $40.7M added.
- The largest Amicus Therapeutics seller in Q2 2019 was Fidelity Investments, an estimated $104M sold.
Based on aggregated 13F filings for Q2 2019.